CI

At a glance

ClinicalIndex Comparison Record
Phase 1Recruiting· 172 target
Drug / intervention
Azenosertib +5 moredrug
Likely dose
Not stated in record
Key inclusion· 9
  • ✓FIGO Stage III/IV high-grade serous or endometrioid ovarian, fallopian tube, or peritoneal carcinoma
  • ✓Part 1: 1 or 2 prior therapeutic regimens in advanced/metastatic setting with at least one containing cisplatin or carboplatin
  • ✓Part 1: Platinum-resistant disease (PFI <6 months) or platinum-refractory disease allowed
  • ✓Part 2 Dose Escalation: 6 cycles platinum-based doublet chemotherapy as most recent therapy in 1L or 2L setting
Key exclusion· 4
  • ✕Abdominal adenocarcinoma of unknown origin or borderline ovarian tumor
  • ✕Carcinosarcomas (including those with serous component)
  • ✕Serious illness or medical condition(s)
  • ✕Active (uncontrolled, metastatic) second malignancies or requiring therapy

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04516447
NCT04516447Phase 1RecruitingOn TrackUpdated 2mo ago
Long Recruiting
CompareCT.gov

A Phase 1b Study of ZN-c3 in Combination With Chemotherapy or Bevacizumab in Subjects With Ovarian, Peritoneal, or Fallopian Tube Cancer

K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc·interventional·Posted Aug 18, 2020·Updated Apr 7, 2026

In Brief

A Phase 1 clinical trial evaluating Azenosertib, Carboplatin, and 4 other interventions for Solid Tumor and 3 related conditions. Currently recruiting, targeting 172 participants across 24 sites in 7 countries.

Detailed Summary

This is a Phase 1b open-label, multicenter study, evaluating the safety, tolerability, preliminary clinical activity, pharmacokinetics (PK), and pharmacodynamics of azenosertib (ZN-c3) in combination with other drugs.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSolid Tumor, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
CountriesAustralia, Bosnia and Herzegovina, Bulgaria, Georgia, Serbia, South Korea, United States
Collaborators--

Timeline

Phase 1Recruiting
20212022202320242025202620272028
First PostedAug 18, 2020
Enrollment StartOct 26, 2020
Primary CompletionJun 30, 2028
TodayJul 2, 2026
Enrollment to primary: 7.7 yearsPosted 5.9 years agoPrimary completion in 2.0 years

Interventions

Azenosertibdrug

Investigational drug

Carboplatindrug

Carboplatin is an approved drug

Pegylated liposomal doxorubicindrug

Pegylated liposomal doxorubicin (PLD) is an approved drug

Paclitaxeldrug

Paclitaxel is an approved drug

Gemcitabinedrug

Gemcitabine is an approved drug

Bevacizumabbiological

Bevacizumab is an approved drug